Carbapenems are potent and broad-spectrum β-lactam antibiotics traditionally reserved for the treatment of the most serious infections ([@B60]). The emergence and dissemination of carbapenem-resistant Gram-negative pathogens including *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and Enterobacteriaceae is a significant contributor to patient morbidity and mortality ([@B172]; [@B228]; [@B121], [@B122]; [@B138]). Despite radical efforts in infection control ([@B229]) and improvements in rapid molecular diagnostics ([@B41]; [@B160]), carbapenem-resistant Gram-negative bacilli remain a formidable threat as few antimicrobial agents are reliably active and very little is expected to be available in the near future.

Clinicians hold that the increasing prevalence of extended-spectrum β-lactamases (ESBLs) among *Klebsiella pneumoniae* and *Escherichia coli* in the 1980s and 1990s contributed to the increased consumption of carbapenems. Experience implied that delayed administration of carbapenems in at-risk patients led to poor clinical outcomes ([@B173]; [@B68]). Thus, carbapenems (i.e., imipenem, meropenem, ertapenem, and doripenem) became vital tools in the treatment of healthcare-associated and severe community-acquired infections. Despite heavy reliance on these agents, carbapenem resistance in Enterobacteriaceae, common causes of both community and healthcare-associated infections, remained rare until the past decade.

Carbapenem resistance among Gram-negative bacteria results from one or more of the following mechanisms: (i) hyperproduction or derepression of Ambler class C β-lactamases (AmpC β-lactamases) or ESBLs (e.g., sulfhydryl variable (SHV), temoneira (TEM), cefotaxime (CTX-M) type β-lactamases) with loss or alteration in outer membrane porins; (ii) augmented drug efflux; (iii) alterations in penicillin binding proteins (PBPs); (iv) carbapenemase production ([@B171]). Carbapenemases belong to three molecular classes of β-lactamases, Ambler class A, B, and D ([@B7]; [@B30]). Our aim is to provide a status report of the molecular diversity and epidemiology of carbapenemases as well as current and future therapeutics. The increasing public safety concerns associated with organisms harboring these enzymes has created significant turmoil. Regrettably, the situation is critical and our patients are in peril.

AMBLER CLASS A CARBAPENEMASES
=============================

Few Ambler class A β-lactamases demonstrate carbapenem-hydrolyzing activity and, up until a decade ago, these were rarely recovered. Class A carbapenemases include: *K. pneumoniae* carbapenemase (KPC), Guiana extended-spectrum (GES), non-metallo-carbapenemase-A (Nmc-A)/imipenem-resistant (IMI), *Serratia marcescens* enzyme (SME), serratia fonticola carbapenemase (SFC), and BIC β-lactamases (**Table [1](#T1){ref-type="table"}**; [@B258]). With the notable exception of KPCs, the clinical isolation of these types of carbapenemases is relatively limited.

###### 

Class A carbapenemases[\*](#T1fn01){ref-type="fn"}.

  Enzyme                               Year isolated or described   Organism(s)                                                          Origin and geographic distribution        Location                               Reference
  ------------------------------------ ---------------------------- -------------------------------------------------------------------- ----------------------------------------- -------------------------------------- -------------------------
  Nmc-A                                1990                         *Enterobacter cloacae*                                               France, Argentina, USA                    Chromosomal                            [@B162]
  IMI-1                                1984                         *Enterobacter cloacae*                                               USA                                       Chromosomal                            [@B214]
  IMI-2                                1999                         *Enterobacter asburiae*, *Enterobacter cloacae*                      USA[^†^](#T1fn02){ref-type="fn"}, China   Plasmid                                [@B12], [@B272]
  SME-1                                1982                         *S. marcescens*                                                      UK, USA                                   Chromosomal                            [@B155]
  SME-2                                1992                         *S. marcescens*                                                      USA, Canada, Switzerland                  Chromosomal                            [@B54], [@B201], [@B34]
  SME-3                                2003                         *S. marcescens*                                                      USA                                       Chromosomal                            [@B210]
  SFC-1                                2003                         *S. fonticola*                                                       Portugal[^†^](#T1fn02){ref-type="fn"}     Chromosomal                            [@B91]
  GES-2                                2000                         *P. aeruginosa*                                                      South Africa                              Plasmid                                [@B252]
  GES-4                                2002                         *K. pneumoniae*                                                      Japan                                     Plasmid                                [@B253]
  GES-5                                2001                         *K. pneumoniae*, *E. coli*, *P. aeruginosa*                          Greece, Korea, worldwide                  Plasmid                                [@B103], [@B249]
  GES-6                                2003                         *K. pneumoniae*                                                      Greece                                    Plasmid                                [@B249]
  GES-11                               2008                         *Acinetobacter baumannii*                                            France                                    Plasmid                                [@B148]
  GES-14                               2010                         *A. baumannii*                                                       France                                    Plasmid                                [@B20]
  KPC-1[^‡^](#T1fn03){ref-type="fn"}   1996                         *K. pneumoniae*                                                      USA                                       Plasmid                                [@B268]
  KPC-2                                1998                         Enterobacteriaceae, *P. aeruginosa*, *Acinetobacter* spp.            USA and worldwide                         Plasmid[^§^](#T1fn04){ref-type="fn"}   [@B268]
  KPC-3                                2000                         Enterobacteriaceae, *Acinetobacter* spp.                             USA and worldwide                         Plasmid                                [@B262]
  KPC-4                                2003                         *Enterobacter cancerogenus*, *K. pneumoniae*, *Acinetobacter* spp.   Scotland, Puerto Rico                     Plasmid                                [@B169], [@B218]
  KPC-5                                2006                         *P. aeruginosa*                                                      Puerto Rico                               Plasmid                                [@B261]
  KPC-6                                2003                         *K. pneumoniae*                                                      Puerto Rico                               Plasmid                                [@B13], [@B219]
  KPC-7                                2007                         *K. pneumoniae*                                                      USA                                       Plasmid                                [@B176]
  KPC-8                                2008                         *K. pneumoniae*                                                      Puerto Rico                               Plasmid                                [@B56]
  KPC-9                                2009                         *E. coli*                                                            Israel                                    Plasmid                                [@B86]
  KPC-10                               2009                         *Acinetobacter* spp.                                                 Puerto Rico                               Plasmid                                [@B217]
  KPC-11                               2009                         *K. pneumoniae*                                                      Greece                                    Unknown                                [@B51]
  KPC-12                               2010                         *E. coli*                                                            China                                     Unknown                                
  KPC-13                               2010                         *Enterobacter cloacae*                                               Thailand                                  Unknown                                
  BIC-1                                2009                         *P. fluorescens*                                                     France[^†^](#T1fn02){ref-type="fn"}       Chromosomal                            [@B83]

Adapted from [@B258].

Environmental isolates.

KPC-1 was later found to be the same enzyme as KPC-2 ([@B95]).

Chromosomal expression of *bla*~KPC-2~ has been described in *P. aeruginosa* ([@B250]).

Non-metallo-carbapenemase-A is a chromosomal carbapenemase originally isolated from *Enterobacter cloacae* in France ([@B162]). Currently, reports of this particular β-lactamase are still rare ([@B206]; [@B40]; [@B166]). IMI-1 was initially recovered from the chromosome of an *Enterobacter cloacae* isolate in the southwestern USA ([@B214]). A variant of IMI-1, IMI-2, has been identified on plasmids isolated from environmental strains of *Enterobacter asburiae* in USA rivers ([@B12]).

SME-1 (*S. marcescens* enzyme) was originally identified in an isolate of *S. marcescens* from a patient in London in 1982 ([@B266]). SME-2 and SME-3 were subsequently isolated in the USA, Canada, and Switzerland ([@B155]; [@B211], [@B210]; [@B55]; [@B201]; [@B34]). Chromosomally encoded SME-type carbapenemases continue to be isolated at a low frequency in North America ([@B54],[@B55]; [@B70]; [@B139]). Both SFC-1 and BIC-1 are chromosomal serine carbapenemases recovered from environmental isolates. The former from a *S. fonticola* isolate in Portugal ([@B91]) and the latter from *Pseudomonas fluorescens* isolates recovered from the Seine River ([@B83]).

The GES-type β-lactamases are acquired β-lactamases recovered from *P. aeruginosa*, Enterobacteriaceae, and *A. baumannii* ([@B196]; [@B38]). The genes encoding these β-lactamase have often, but not exclusively, been identified within class 1 integrons residing on transferable plasmids ([@B24]; [@B258]). GES-1 has a similar hydrolysis profile to other ESBLs, although they essentially spare monobactams. Several GES β-lactamases are described with six (i.e., GES-2, GES-4, GES-5, GES-6, GES-11, and GES-14), demonstrating detectable carbapenemase activity in the setting of amino acid substitutions at their active sites (specifically at residue 104 and 170; [@B258]; [@B113]). These GES-type carbapenemases have been described in Europe, South Africa, Asia, and the Middle East ([@B200]; [@B103]; [@B49]; [@B148]; [@B22], [@B24]).

Currently, most carbapenem resistance among Enterobacteriaceae in the USA and Israel is attributed to plasmid-mediated expression of a KPC-type carbapenemase ([@B66]; [@B161]; [@B88]; [@B229]). KPC-producing Enterobacteriaceae are considered endemic to Greece along with other carbapenemases, specifically VIM-type \[Verona integron-encoded metallo-β-lactamases (MBLs); [@B33]\]. KPCs efficiently hydrolyze carbapenems as well as penicillins, cephalosporins, and aztreonam and are not overcome *in vitro* by clinically available β-lactamase inhibitors (i.e., clavulanic acid, sulbactam, tazobactam -- in fact these are hydrolyzed). These enzymes have been identified in several genera of Enterobacteriaceae as well as *Pseudomonas* spp. and *A. baumannii* ([@B145]; [@B269]; [@B28]; [@B250]; [@B31]; [@B213]; [@B238]; [@B217]; [@B140]; [@B78]).

Carbapenem resistance secondary to KPC production was first described in a *K. pneumoniae* recovered in North Carolina in 1996 ([@B268]). To date 12 KPC subtypes (KPC-2 to KPC-13; [@B219]; [@B111]; [@B157]; [@B261]; [@B85]) have been reported with the vast majority of analyzed isolates expressing either KPC-2 or KPC-3.

The *bla*~KPC~ gene has been mapped to a highly conserved Tn*3*-based transposon, Tn*4401* (**Figure [1A](#F1){ref-type="fig"}**), and five isoforms of Tn*4401* are described ([@B154]; [@B47]; [@B110]). Plasmids carrying *bla*~KPC~ are of various sizes and many carry additional genes conferring resistance to fluoroquinolones and aminoglycosides thus limiting the antibiotics available to treat infections with KPC-producing pathogens ([@B64]; [@B216]). *bla*~KPC~ has rarely been mapped to a chromosomal location ([@B250]; [@B36]).

![**FIGURE 1. Basic genetic construct of select carbapenemase genes. (A)** Schematic representation of Tn*4401* type of transposon associated with *bla*~KPC~ which includes a transposase gene (*tnp*A), a resolvase gene (*tnp*R), as well as insertion sequences, IS*Kpn6*and IS*Kpn7* ([@B47]). **(B)** The *bla*~NDM-1~ construct demonstrates IS*Aba125* insertion sequence(s) upstream of the *bla*~NDM-1~ and a novel bleomycin resistance gene, *ble*~MBL~, downstream ([@B59]). **(C)** *bla*~OXA-48~ is often mapped to a Tn*1999* composite transposon where it is bracketed between two copies of the same insertion sequence, IS*1999.* Downstream of *bla*~OXA-48~ lies a *lysR*gene which encodes for a regulatory protein ([@B186]).](fmicb-04-00048-g001){#F1}

A predominant strain of *K. pneumoniae* appears responsible for outbreaks and the international spread of KPC-producing *K. pneumoniae* ([@B264]; [@B111]; [@B226]). Congruent pulsed-field gel electrophoresis (PFGE) patterns also suggest a clonal relationship between outbreak-associated strains of KPC-producing *K. pneumoniae* recovered from different areas that are endemic ([@B157]; [@B263]). The Centers for Disease Control and Prevention (CDC) performed PFGE and multilocus sequence typing (MLST) on isolates submitted to their reference laboratory from 1996 to 2008. A dominant PFGE pattern was observed and noted to be of a specific MLST type, ST 258 ([@B111]). A second sequence type, ST 14, was common in institutions in the Midwest ([@B112]). These findings implied that certain strains of *K. pneumoniae* may be more apt to obtain and retain the *bla*~KPC~ gene. Another study, however, analyzing 16 KPC-2 producing *K. pneumoniae* isolates from different geographic regions demonstrated diverse PFGE patterns and MLST types. This included four different MLST types in Colombia (ST 14, ST 337, ST 338, and ST 339) and two in Israel (ST 227 and ST 340). Although this study analyzed a smaller number of isolates, these findings suggest that the global propagation of KPC-2 is more complicated than the successful expansion of a fixed number of clones ([@B47]; [@B209]). More recently, a study evaluating the MLST types associated with widespread KPC-2 production in *K. pneumoniae* in Greece suggested that although ST 258 predominates at least 10 additional sequence types were found to carry *bla*~KPC-2~. Of note three (i.e., ST 147, ST 323, and ST 383) carried both KPC-2 as well as genes encoding VIM-type MBLs ([@B80]; [@B263]). A retrospective study in Cleveland documented the presence of ST 36 in a long-term care facility for children ([@B249]).

*Klebsiella pneumoniae* carbapenemases-production can confer variable levels of carbapenem resistance with reported minimum inhibitory concentrations (MICs) ranging from susceptible to ≥ μg/mL. Analysis of isolates displaying high-level carbapenem resistance demonstrated that increased phenotypic resistance may be due to increased *bla*~KPC~ gene copy number or the loss of an outer membrane porin, OmpK35 and/or OmpK36. The highest level of imipenem resistance was seen with isolates lacking both porins and with augmented KPC enzyme production ([@B110]).

AMBLER CLASS B CARBAPENEMASES: METALLO-β-LACTAMASES
===================================================

Class B β-lactamases (**Table [2](#T2){ref-type="table"}**) are referred to as MBLs and require a metal ion, usually zinc, for β-lactam hydrolysis ([@B256]). Due to the dependence on Zn^2+^, catalysis is inhibited in the presence of metal-chelating agents like ethylenediaminetetraacetic acid (EDTA). MBL expression in Gram-negative bacteria confers resistance to penicillins, cephalosporins, and carbapenems. MBLs are not inhibited by the presence of commercially available β-lactamase inhibitors and susceptibility to monobactams (e.g., aztreonam) appears to be preserved in the absence of concomitant expression of other resistance mechanisms (e.g., ESBL production). The more geographically widespread MBLs include IMP (imipenem-resistant), VIM, and New Delhi metallo-β-lactamase (NDM).

###### 

Metallo-β-lactamases.

  Enzyme            Year isolated or described   Organism(s)                                                    Geographic distribution              Location                 Reference
  ----------------- ---------------------------- -------------------------------------------------------------- ------------------------------------ ------------------------ ---------------------------
  IMP-1 to IMP-42   1988                         Enterobacteriaceae, *Pseudomonas* spp., *Acinetobacter* spp.   Worldwide                            Plasmid or chromosomal   [@B165], [@B215]
  VIM-1 to VIM-37   1997                         Enterobacteriaceae, *Pseudomonas* spp., *Acinetobacter* spp.   Worldwide                            Plasmid or chromosomal   [@B120], [@B197]
  SPM-1             2001                         *P. aeruginosa*                                                Brazil[\*](#T2fn01){ref-type="fn"}   Chromosomal              [@B240]
  GIM-1             2002                         *P. aeruginosa*                                                Germany                              Plasmid                  [@B39]
  SIM-1             2003--2004                   *A. baumannii*                                                 Korea                                Chromosomal              [@B124]
  NDM-1 to NDM-7    2006                         Enterobacteriaceae, *Acinetobacter*spp., *Vibrio cholerae*     Worldwide                            Plasmid or chromosomal   [@B270], [@B106], [@B158]
  AIM-1             2007                         *P. aeruginosa*                                                Australia                            Chromosomal              [@B271]
  KHM-1             1997                         *C. freundii*                                                  Japan                                Plasmid                  [@B231]
  DIM-1             2007                         *P. stutzeri*                                                  Netherlands                          Plasmid                  [@B184]
  SMB-1             2010                         *S. marcescens*                                                Japan                                Chromosomal              [@B254]
  TMB-1             2011                         *Achromobacter xylosoxidans*                                   Libya                                Chromosomal              [@B61]
  FIM-1             2007                         *P. aeruginosa*                                                Italy                                Chromosomal              [@B202]

Single report of SPM-1 in Europe linked to healthcare exposure in Brazil ([@B225]).

Chromosomal MBLs were the first to be identified and are the cause of carbapenem resistance observed in *Bacillus cereus*, *Aeromonas* spp., and *Stenotrophomonas maltophilia* ([@B256]). However, of growing concern are the "mobile" MBLs that have been reported since the mid-1990s. Although most frequently found in carbapenem-resistant isolates of *P. aeruginosa* and occasionally *Acinetobacter* spp., there is growing isolation of these enzymes in Enterobacteriaceae.

Prior to the description of NDM-1, frequently detected MBLs include IMP-type and VIM-type with VIM-2 being the most prevalent. These MBLs are embedded within a variety of genetic structures, most commonly integrons. When these integrons are associated with transposons or plasmids they can readily be transferred between species.

In 1991, IMP-1, a plasmid-mediated MBL, was identified in an isolates of *S. marcescens* from Japan ([@B102]). Since then plasmid-mediated carbapenem resistance secondary to IMP-1 spread widely in Japan, Europe, Brazil, and other parts of Asia and in several species of Gram-negative bacilli including *Acinetobacter* spp. and Enterobacteriaceae. At the present time, 42 variants of IMP have been identified with most cases of IMP-mediated carbapenem resistance being reported from Asia and among *P. aeruginosa* ([@B30]).

A more commonly recovered MBL is the VIM-type enzyme. VIM-1 was first described in Italy in 1997 in *P. aeruginosa* ([@B120]). VIM-2 was next discovered in southern France in *P. aeruginosa* cultured from a neutropenic patient in 1996 ([@B197]). Although originally thought to be limited to non-fermenting Gram-negative bacilli, VIM-type MBLs are being increasingly identified in Enterobacteriaceae as well ([@B81]; [@B108]; [@B146]; [@B33]). To date, 37 variants of VIM have been described with VIM-2 being the most common MBL recovered worldwide.

Other more geographically restricted MBLs include SPM-1 (Sao Paulo MBL), which has been associated with hospital outbreaks in Brazil ([@B240]; [@B223]); GIM-1 (German imipenemase) isolated in carbapenem-resistant *P. aeruginosa* isolates in Germany ([@B39]); SIM-1 (Seoul imipenemase) isolated from *A. baumannii* isolates in Korea ([@B124]); KHM-1 (Kyorin Health Science MBL) isolated from a *C. freundii* isolate in Japan ([@B231]); AIM-1 (Australian imipenemase) isolated from *P. aeruginosa* in Australia ([@B271]); DIM-1 (Dutch imipenemase) isolated from a clinical *P. stutzeri* isolate in the Netherlands ([@B184]); SMB-1 (*S. marcescens* MBL) in *S. marcescens* in Japan ([@B254]); TMB-1 (Tripoli MBL) in *Achromobacter xylosoxidans* in Libya ([@B61]), and FIM-1 (Florence imipenemase) from a clinical isolate of *P. aeruginosa* in Italy ([@B202]). With the notable exception of SPM-1, these MBLs have remained confined to their countries of origin ([@B225]).

NDM-1 was first identified in 2008. Due to its rapid international dissemination and its ability to be expressed by numerous Gram-negative pathogens, NDM is poised to become the most commonly isolated and distributed carbapenemase worldwide. Initial reports frequently demonstrated an epidemiologic link to the Indian subcontinent where these MBLs are endemic ([@B114]). Indeed, retrospective analyses of stored isolates suggest that NDM-1 may have been circulating in the subcontinent as early as 2006 ([@B37]). Despite initial controversy, the Balkans may be another area of endemicity for NDM-1 ([@B235]; [@B105]; [@B133]; [@B89]). Sporadic recovery of NDM-1 in the Middle East suggests that this region may be an additional reservoir ([@B182], [@B191]; [@B163]; [@B79]).

Like KPCs, the conveniences of international travel and medical tourism have quickly propelled this relatively novel MBL into a formidable public health threat. Gram-negative bacilli harboring *bla*~NDM~ have been identified worldwide with the exception of Central and South America.

NDM-1 was first identified in Sweden in a patient of Indian descent previously hospitalized in India ([@B270]). The patient was colonized with a *K. pneumoniae* and an *E. coli* carrying *bla*~NDM-1~ on transferable plasmids. In the UK, an increase in the number of clinical isolates of carbapenem-resistant Enterobacteriaceae was seen in both 2008 and 2009. A UK reference laboratory reported that at least 17 of 29 patients found to be harboring NDM-1 expressing Enterobacteriaceae had a history of recent travel to the Indian subcontinent with the majority having been hospitalized in those countries ([@B114]).

European reports suggest that horizontal transfer of *bla*~NDM-1~ exists within hospitals outside endemic areas. Of overwhelming concern are the reported cases without specific contact with the healthcare system locally or in endemic areas suggesting autochthonous acquisition ([@B114]; [@B115]; [@B10]; [@B25]; [@B159]).

Surveillance of public water supplies in India indicates that exposure to NDM-1 may be environmental. [@B257] analyzed samples of public tap water and seepage water from sites around New Delhi. The results were disheartening in that *bla*~NDM-1~ was detected by PCR in 4% of drinking water samples and 30% of seepage samples. In this survey, carriage of *bla*~NDM-1~ was noted in 11 species of bacteria not previously described, including virulent ones like *Shigella boydii* and *Vibrio cholerae*.

The rapid spread of NDM-1 highlights the fluidity and rapidity of gene transfer between bacterial species. Although *bla*~NDM-1~ was initially and repeatedly mapped to plasmids isolated from carbapenem-resistant *E. coli* and *K. pneumoniae*, reports of both plasmid and chromosomal expression of *bla*~NDM-1~ has been noted in other species of Enterobacteriaceae as well as *Acinetobacter* spp. and *P. aeruginosa* ([@B148]; [@B20]; [@B22]; [@B163]; [@B171]). Recently, bacteremia with a NDM-1 expressing *V. cholerae* has been described in a patient previously hospitalized in India colonized with a variety of Enterobacteriaceae previously known to be capable of carrying plasmids with *bla*~NDM-1~ ([@B50]).

In contrast to KPCs, the presence of a dominant clone among *bla*~NDM-1~ carrying isolates remains elusive ([@B190]). NDM-1 expression in *E. coli* has been noted among sequence types previously associated with the successful dissemination of other β-lactamases including ST 101 and ST 131 ([@B150]). [@B150] analyzed a relatively large group of *bla*~NDM-1~ expressing *E. coli* from the UK, Pakistan, and India in order to potentially identify a predominant strain responsible for the rapid and successful spread of NDM-1. The most frequent sequence type identified was ST 101. Another study examining a collection of carbapenem-resistant Enterobacteriaceae from India demonstrates the diversity of strains capable of harboring *bla*~NDM-1~. Carriage of *bla*~NDM-1~ was confirmed in 10 different sequence types of *K. pneumoniae* and 5 sequence types of *E. coli* ([@B118]). This multiplicity was confirmed in a study looking at a collection of *bla*~NDM-1~ expressing Enterobacteriaceae from around the world ([@B190]). Of most concern is that NDM-1 has been identified in *E. coli* ST 131, the strain of *E. coli* credited with the global propagation of CTX-M-15 ESBLs ([@B150]; [@B175]; [@B181]; [@B263]). Similar to KPCs, NDM-1 expression portends variable levels of carbapenem resistance and there is often concomitant carriage of a myriad of resistance determinants including other β-lactamases and carbapenemases as well as genes associated with resistance to fluoroquinolones and aminoglycosides ([@B163]).

NDM-1 shares the most homology with VIM-1 and VIM-2. It is a 28-kDa monomeric protein that demonstrates tight binding to both penicillins and cephalosporins ([@B275]). Binding to carbapenems does not appear to be as strong as other MBLs, but hydrolysis rates appear to be similar. Using ampicillin as a substrate, allowed for detailed characterization of the interactions between NDM\'s active site and β-lactams as well as improved evaluation of MBLs unique mechanism of β-lactam hydrolysis. More recent crystal structures of NDM-1 reveal the molecular details of how carbapenem antibiotics are recognized by dizinc-containing MBLs ([@B109]).

To date, NDM-1 remains the most common NDM variant isolated. Seven variants (NDM-1 to NDM-7) exist ([@B106]; [@B158]). It is currently held that *bla*~NDM-1~ is a chimeric gene that may have evolved from *A. baumannii* ([@B241]). Contributing to this theory is the presence of complete or variations of the insertion sequence, IS*Aba125*, upstream to the *bla*~NDM-1~ gene in both Enterobacteriaceae and *A. baumannii* ([@B180]; [@B188]; [@B59]; [@B241]). This insertion sequence has primarily been found in *A. baumannii*.

A recent evaluation of the genetic construct associated with *bla*~NDM-1~ (**Figure [1B](#F1){ref-type="fig"}**) has lead to the discovery of a new bleomycin resistance protein, BRP~MBL~. Evaluation of 23 isolates of *bla*~NDM-1/2~ harboring Enterobacteriaceae and *A. baumannii* noted that the overwhelming majority of them possessed a novel bleomycin resistance gene, *ble*~MBL~ ([@B59]). Co-expression of *bla*~NDM-1~ and *ble*~MBL~ appear to be mediated by a common promoter (*P*~NDM-1~) which includes portions of IS*Aba125*. It is postulated that BRP~MBL~ expression may contribute some sort of selective advantage allowing NDM-1 to persist in the environment.

A contemporary evaluation of recently recovered NDM-1 producing *A. baumannii* isolates from Europe demonstrates that *bla*~NDM-1~ and *bla*~NDM-2~ genes are situated on the same chromosomally located transposon, Tn*125* ([@B23]). Dissemination of *bla*~NDM~ in *A. baumannii* seems be due to different strains carrying Tn*125* or derivatives of Tn*125* rather than plasmid-mediated or clonal ([@B24]; [@B185]).

CARBAPENEM-HYDROLYZING CLASS D β-LACTAMASES
===========================================

Oxacillinases comprise a heterogeneous group of class D β-lactamases which are able to hydrolyze amino- and carboxypenicillins ([@B183]). The majority of class D β-lactamases are not inhibited by commercially available β-lactamase inhibitors but are inhibited *in vitro* by NaCl. Over 250 types of oxacillinases are reported with a minority demonstrating low levels of carbapenem-hydrolyzing activity. This select group of enzymes is also referred to as the carbapenem-hydrolyzing class D β-lactamases (CHDLs; **Table [3](#T3){ref-type="table"}**). CHDLs have been identified most frequently in *Acinetobacter* spp., however, there has been increasing isolation among Enterobacteriaceae, specifically OXA-48 (oxacillinase-48; [@B119]; [@B141]).

###### 

Carbapenem-hydrolyzing class D β-lactamases.

  Enzyme group   Year isolated or described   Organism(s)                                        Geographic distribution                                    Location               Reference
  -------------- ---------------------------- -------------------------------------------------- ---------------------------------------------------------- ---------------------- -----------------
  OXA-23/27      1985/--                      *Acinetobacter baumannii*, *Proteus mirabilis*\*   Europe, USA, Middle East, Asia, Australia                  Plasmid, chromosomal   [@B5], [@B84]
  OXA-24/40      1997                         *A. baumannii*                                     Europe and USA                                             Plasmid, chromosomal   [@B27], [@B136]
  OXA-25         --                           *A. baumannii*                                     Spain                                                      Chromosomal            [@B5]
  OXA-26         1996                         *A. baumannii*                                     Belgium                                                    Chromosomal            [@B5]
  OXA-48         2001                         *K. pneumoniae*, Enterobacteriaceae                Turkey, Middle East, Northern Africa, Europe, India, USA   Plasmid                [@B194]
  OXA-51/66/69   1993                         *A. baumannii*                                     Worldwide                                                  Chromosomal            [@B29], [@B69]
  OXA-58         2003                         *A. baumannii*                                     Europe, USA, Middle East, South America                    Plasmid                [@B198]
  OXA-143        2004                         *A. baumannii*                                     Brazil                                                     Plasmid                [@B97]
  OXA-162        2008                         Enterobacteriaceae                                 Germany                                                    Plasmid                [@B179]
  OXA-163        2008                         *K. pneumoniae*, *E. coli*                         Argentina and Egypt                                        Plasmid                [@B189], [@B1]
  OXA-181        2006                         *K. pneumoniae*, *E. coli*                         India                                                      Plasmid                [@B37]
  OXA-204        2012                         *K. pneumoniae*                                    Tunisia                                                    Plasmid                [@B205]
  OXA-232        2012                         *K. pneumoniae*                                    France                                                     Plasmid                [@B187]

Single isolate described in France.

With the exception of OXA-163 ([@B189]), CHDLs efficiently inactivate penicillins, first generations cephalosporins, and β-lactam/β-lactamase inhibitor combinations, but spare extended-spectrum cephalosporins. Carbapenem hydrolysis efficiency is lower than that of other carbapenemases, including the MBLs, and often additional resistance mechanisms are expressed in organisms demonstrating higher levels of phenotypic carbapenem resistance. These include expression of other carbapenemases, alterations in outer membrane proteins (e.g., CarO, OmpK36; [@B178]; [@B87]; [@B179]), increased transcription mediated by *IS* elements functioning as promoters, increased gene copy number, and amplified drug efflux ([@B199]; [@B178]). Many subgroups of CHDLs have been described. We will focus on those found in *A. baumannii* and Enterobacteriaceae: OXA-23 and OXA-27; OXA-24/40, OXA-25, and OXA-26; OXA-48 variants; OXA-51, OXA-66, OXA-69; OXA-58, and OXA-143.

CHDLs can be intrinsic or acquired. *A. baumannii* does have naturally occurring but variably expressed chromosomal CHDLs, OXA-51, OXA-66, and OXA-69 ([@B29]; [@B93]). For the most part, in isolation the phenotypic carbapenem resistance associated with these oxacillinases is low. However, levels of carbapenem resistance appear to be increased in the presence of specific insertion sequences promoting gene expression ([@B75]; [@B46]). Additional resistance to extended-spectrum cephalosporins can be seen in the setting of co-expression of ESBLs and/or other carbapenemases ([@B37]; [@B141]; [@B179]; [@B251]; [@B205]).

The first reported "acquired" oxacillinase with appreciable carbapenem-hydrolyzing activity was OXA-23. OXA-23, or ARI-1, was identified from an *A. baumannii* isolate in Scotland in 1993 (the isolate was first recovered in 1985; [@B174]). Subsequently, OXA-23 expression has been reported worldwide ([@B149]) and both plasmid and chromosomal carriage of *bla*~OXA-23~ are described. The OXA-23 group includes OXA-27, found in a single *A. baumannii* isolate from Singapore ([@B5]). With the exception of an isolate of *Proteus mirabilis* identified in France in 2002, this group of β-lactamases has been exclusively recovered from *Acinetobacter* species ([@B21]). Increased expression of OXA-23 has been associated with the presence of upstream insertion sequences (e.g., IS*Aba1* and IS*Aba4*) acting as strong promoters ([@B44]).

Another group of CHDLs include OXA-24/40, OXA-25, and OXA-26 ([@B27]; [@B5]). OXA-24 and OXA-40 differ by a few amino acid substitutions and OXA-25 and OXA-26 are point mutation derivatives of OXA-40 ([@B5]). Although primarily linked with clonal outbreaks in Spain and Portugal ([@B26]; [@B136]; [@B51]; [@B2]), OXA-24/40 β-lactamases has been isolated in other European countries and the USA ([@B135]). OXA-40 was in fact the first CHDL documented in the USA ([@B135]).

OXA-58 has also only been detected in *Acinetobacter* spp. initially identified in France ([@B92]; [@B198]), OXA-58 has been associated with institutional outbreaks and has been recovered from clinical isolates of *A. baumannii* worldwide ([@B43]; [@B143]; [@B77]).

As civilian and military personnel began returning from Afghanistan and the Middle East, practitioners noted increasing recovery of *A. baumannii* from skin and soft tissue infections. Drug resistance was associated with expression of both OXA-23 and OXA-58 ([@B100]; [@B230]; [@B177]). Many isolates carrying the *bla*~OXA-58~ gene concurrently carry insertion sequences (e.g., IS*aba1*, IS*Aba2*, or IS*Aba3*) associated with increased carbapenemase production and thus higher levels of carbapenem resistance. In one report increased gene copy number was also associated with a higher level of enzyme production and increased phenotypic carbapenem resistance ([@B17]).

Spread of OXA-type carbapenemases among *A. baumannii* appears to be clonal and in depth reviews of the molecular epidemiology and successful dissemination of these clones have been published ([@B263]; [@B273]). Two MLST schemes with three loci in common exist for *A. baumannii* -- the PubMLST scheme ([@B13]) and the Pasteur scheme ([@B56]). Both schemes assign different sequence types into clonal complexes (CC). Sequence types and CC from both schemes can be further categorized into the international (European) clones I, II, and III. It should be noted, however, that the molecular taxonomy of *A. baumannii* continues to evolve ([@B95]). OXA-23 producing *A. baumannii* predominantly belong to international clones I and II with a notable proportion being part of CC92 (PubMLST; [@B149]; [@B3]). Similarly, *A. baumannii* isolates associated with epidemic spread of OXA-24/40 in Portugal and Spain appear are incorporated in international clone II ([@B51]; [@B86]) and ST 56 (PubMLST; [@B2]). OXA-58 expressing *A. baumannii* have been associated with international clones I, II, and II and a variety of unrelated sequence types ([@B57]; [@B84]).

OXA-48 was originally identified in a carbapenem-resistant isolate of *K. pneumoniae* in Turkey ([@B195]). Early reports suggested that this enzyme was geographically restricted to Turkey. In the past few years, however, the enzyme has been recovered from variety of Enterobacteriaceae and has successfully circulated outside of Turkey with reports of isolation in the Middle East, North Africa, Europe ([@B35]), and most recently the USA ([@B119]; [@B141]). The Middle East and North Africa may be secondary reservoirs for these CHDLs ([@B90]; [@B187]). Indeed, the introduction of OXA-48 expressing Enterobacteriaceae in some countries has been from patients from the Middle East or Northern Africa ([@B52]; [@B4]; [@B192]; [@B33]). In the USA, the first clinical cases were associated with ST 199 and ST 43 ([@B141]).

At least six OXA-48 variants (e.g., OXA-48, OXA-162, OXA-163, OXA-181, OXA-204, and OXA-232) have been identified. OXA-48 is by far the most globally dispersed and its epidemiology has been recently reviewed ([@B187]). Unlike KPCs and NDM-1 which have been associated with a variety of plasmids, a single 62 kb self-conjugative IncL/M-type plasmid has contributed to a large proportion of the distribution of *bla*~OXA-48~ in Europe ([@B203]). Sequencing of this plasmid (pOXA-48a) notes that *bla*~OXA-48~ had been integrated through the acquisition of a Tn*1999* composite transposon (**Figure [1C](#F1){ref-type="fig"}**; [@B186]) *bla*~OXA-48~ appears to be associated with a specific insertion sequence, IS*1999* ([@B195], [@B186]). A variant of Tn*1999*, Tn*1999.2*, has been identified among isolates from Turkey and in Europe ([@B35]; [@B203]). Tn*1999.2* harbors an IS*1R* element within the IS*1999*. OXA-48 appears to have the highest affinity for imipenem of the CHDLs specifically those harboring *bla*~OXA-48~ within a Tn*1999.2* composite transposon ([@B58]). Three isoforms of the Tn*1999* transposon have been described ([@B82]).

Although much of the spread of OXA-48 is attributed to a specific plasmid, outbreak evaluations demonstrate that a variety of strains have contributed to dissemination of this emerging carbapenemase in *K. pneumoniae*. The same *K. pneumoniae* sequence type, ST 395, harboring *bla*~OXA-48~ was identified in Morocco, France, and the Netherlands ([@B48]; [@B203]). ST 353 was associated with an outbreak of OXA-48 producing *K. pneumoniae* in London ([@B263]) and ST 221 with an outbreak of OXA-48 in Ireland ([@B33]). OXA-48 production in *K. pneumoniae*, like KPC-expressing *K. pneumoniae*, has also been associated with ST 14 ([@B195]) and a recent outbreak in Greece was associated with ST 11 ([@B251]).

*bla*~OXA-48~ is remarkably similar to *bla*~OXA-54~, a β-lactamase gene intrinsic to *Shewanella oneidensis* ([@B193]). *Shewanella* spp. are relatively ubiquitous waterborne Gram-negative bacilli and are proving to be a potential environmental reservoir for OXA-48 like carbapenemases as well as other resistance determinants ([@B94]; [@B194]; [@B204]).

OXA-163, a single amino acid variant of OXA-48, was identified in isolates of *K. pneumoniae* and *Enterobacter cloacae* from Argentina and is unique in that it has activity against extended-spectrum cephalosporins ([@B189]). OXA-163 also has been identified in Egypt, which has a relatively prevalence of OXA-48, in patients without epidemiologic links to Argentina ([@B1]).

OXA-181 was initially identified among carbapenem-resistant Enterobacteriaceae collected from India ([@B37]). OXA-181 differs from OXA-48 by four amino acids, however, appears to be nestled in an entirely different genetic platform. The *bla*~OXA-181~ gene has been mapped to a different group of plasmids, the ColE family, and has been associated with an alternative insertion sequence, IS*Ecp1*. The latter insertion sequence has been associated with the acquisition of other β-lactamases including CTX-M-like ESBLs. Like, OXA-48, it appears that OXA-181 may have evolved from a waterborne environmental species *Shewanella xiamenensis* ([@B204]).

OXA-204 differs from OXA-48 by a two amino acid substitution. It was recently identified in a clinical *K. pneumoniae* isolate from Tunisia ([@B205]). Its genetic construct appears to be similar to that of OXA-181. OXA-232 was recently identified among *K. pneumoniae* isolates in France ([@B187]).

OXA-143 is a novel plasmid-borne carbapenem-hydrolyzing oxacillinase recovered from clinical *A. baumannii* isolates in Brazil ([@B97]). Information regarding its significance and prevalence continues to evolve ([@B9]; [@B260]; [@B147]).

AVAILABLE AGENTS AND DRUGS IN DEVELOPMENT
=========================================

Few antimicrobials are currently available to treat infections with carbapenemase-producing Gram-negative bacteria. Carriage of concurrent resistance determinants can result in decreased susceptibility non-β-lactams including the fluoroquinolones and aminoglycosides thus further compromising an already limited antimicrobial arsenal. What frequently remains available are the polymyxins (including colistin), tigecycline, and fosfomycin but susceptibilities to these agents are unpredictable ([@B72]).

The reintroduction of polymyxins, both polymyxin B and colistin overlaps with the evolution of carbapenem resistance among Gram-negative bacilli. The clinical "resurgence" of these agents is well documented ([@B73]; [@B126]; [@B116]). Some experts advocate for the use of polymyxins in combination with other agents like rifampicin ([@B99]; [@B244]). *In vitro* evaluations of different combinations including carbapenems, rifamycins, and/or tigecycline demonstrate variable results ([@B16]; [@B19]; [@B53]; [@B104]). Most evaluations of the clinical outcomes or "effectiveness" of combination therapies have been retrospective ([@B212]; [@B242]). Prospective clinical trials evaluating the superiority of colistin-based combination therapy over monotherapy are in their infancy. A real interest in combination therapy persists due to the concern of hetero-resistance ([@B127]; [@B207]; [@B123]; [@B267]; [@B142]).

Early evaluations of the glycylcycline, tigecycline, demonstrated favorable *in vitro* activity against ESBL-producing Enterobacteriaceae and specific isolates of carbapenem-resistant *A. baumannii* and Enterobacteriaceae ([@B28]; [@B76]; [@B164]; [@B40]; [@B259]). Tigecycline remains untested in prospective trials and reports of resistance are increasing ([@B156]; [@B8]; [@B259]; [@B236]). The role of tigecycline in treating primary bloodstream infections or urinary tract infections remains undefined due less than therapeutic concentrations of drug achieved in the serum ([@B221]) and urine ([@B227]). We also note that meta-analyses of pooled data from trials evaluating the use of tigecycline for a variety of indications suggest there is a excess mortality associated with the use of tigecycline over comparator regimens ([@B32]; [@B237]; [@B265]; [@B248]). However, in the absence of other tested regimens tigecycline may be an appropriate or perhaps the only therapeutic option.

Growing resistance to both the polymyxins and tigecycline has resulted the revisiting of older drugs including chloramphenicol, nitrofurantoin, and temocillin ([@B134]). Fosfomycin is also one of these earlier antibiotics being reassessed ([@B71]). In an *in vitro* evaluation of 68 KPC-expressing *K. pneumoniae* isolates, fosfomycin demonstrated *in vitro* activity against 87% of tigecycline and/or polymyxin non-susceptible isolates and 83% of isolates that were resistant to both ([@B63]). Fosfomycin may be a potential therapeutic option for patients infected with carbapenemase-producing Enterobacteriaceae if the infection is localized to the genitourinary tract. Unfortunately, fosfomycin does not demonstrate reliable activity against non-urinary pathogens. Fosfomycin demonstrated activity against only 30.2% of 1693 multidrug-resistant (MDR) *P. aeruginosa* isolates and 3.5% of 85 MDR *A. baumannii* isolates ([@B74]). The individual studies included in this review did not employ uniform MDR definitions or consistent susceptibility breakpoints. Moreover, access to the parenteral fosfomycin is limited and the threshold for resistance is low ([@B220]; [@B107]). Concerns regarding the emergence of resistance have lead to an increasing interest in the utility of combination therapy ([@B144]; [@B16]; [@B234]).

Few agents are in the advanced stages of development with demonstrable *in vitro* activity against carbapenemase-producing organisms. These include β-lactamase inhibitors, aminoglycoside derivatives, polymyxin derivatives, and novel monobactams and monobactams-β-lactamase inhibitor combinations.

Avibactam, or NXL104, is a β-lactamase inhibitor which has been tested in combination with ceftazidime, ceftaroline, and aztreonam against several carbapenemase-producing Enterobacteriaceae with impressive decreases in MICs ([@B130], [@B132]; [@B65]; [@B153]). Cephalosporin--avibactam combinations do not inhibit MBLs. Avibactam in combination with aztreonam, however, does seem to demonstrate activity against isolates harboring a variety of carbapenem resistance mechanisms including MBLs ([@B132]). Regrettably, the avibactam and aztreonam combination is not currently in clinical trials. The combination of ceftazidime--avibactam has been evaluated against collections of non-fermenting Gram-negative pathogens and its role remains undefined ([@B152]). In some evaluations of ceftazidime non-susceptible isolates of *P. aeruginosa* decrease MICs were noted with the addition of avibactam ([@B152]; [@B255]; [@B45]; [@B125]). The combinations of ceftaroline--avibactam and ceftazidime--avibactam are currently in clinical trials.

Methylidene penems (penem-1 and penem-2) are β-lactamase inhibitors and appear to be potent inhibitors of KPC-2 ([@B170]). The combination of cefepime with penem-1 demonstrated lower cefepime MICs in 88.1% of the 42 KPC-producing *K. pneumoniae* isolates evaluated ([@B62]). MK-7655 is a novel β-lactamase being evaluated in combination with imipenem against carbapenem-resistant Gram-negative bacilli ([@B98]).

ME1071, formerly CP3242 ([@B14]), is a maleic acid derivative that competitively inhibits MBLs. Earlier studies demonstrated concentration-dependent decreases in carbapenem MICs in MBL-producing *P. aeruginosa* ([@B101]), *A. baumannii*, and select Enterobacteriaceae ([@B232]) A contemporary pre-clinical evaluation of ME1071 in combination with various type 2 carbapenems (i.e., biapenem, doripenem, meropenem, imipenem) confirms remarkable decreases in the carbapenem MICs for Enterobacteriaceae and *A. baumannii* harboring IMP, VIM, and NDM-type MBLs ([@B128]). Irrespective of the candidate carbapenem, ME1071 activity against NDM MBLs was less than that of VIM-type and IMP-type MBLs. Of note, biapenem was the carbapenem with the lowest baseline MICs to the MBLs, but it is commercially unavailable in many countries including the USA. Other MBL-specific inhibitors are in pre-clinical development ([@B42]).

Plazomicin (ACHN-490) is an aminoglycoside derivative with potent activity against some carbapenem-resistant Gram-negative bacilli ([@B274]). Studies have noted that susceptibilities to aminoglycosides vary among KPC-producing *K. pneumoniae*. In one evaluation, 48% of 25 tested isolates were susceptible to amikacin, 44% to gentamicin, and 8% to tobramycin. Plazomicin demonstrated an MIC~90~ significantly lower than that of amikacin ([@B67]). *In vitro* studies also indicate that depending on the aminoglycoside resistance mechanisms present, Plazomicin may have activity against select isolates of *P. aeruginosa* and *A. baumannii* ([@B6]; [@B117]). Susceptibility to plazomicin in the setting of resistance to other aminoglycosides appears to be dependent on the mechanism of aminoglycoside resistance ([@B131]).

NAB739 and NAB7061 are polymyxin derivatives that may be less nephrotoxic than commercially available polymyxins. In a small *in vitro* study, NAB739 displayed activity against nine carbapenemase-producing polymyxin-susceptible isolates of Enterobacteriaceae ([@B246]). A contemporary evaluation of NAB739 demonstrated higher MICs compared to those of polymyxin B in a collection of polymyxin-susceptible and non-susceptible Enterobacteriaceae, *P. aeruginosa*, and *A. baumannii* ([@B245]). NAB7061 when used in combination with rifampicin or clarithromycin demonstrated synergistic activity against seven strains of carbapenemase-producing Gram-negative bacilli including one polymyxin-resistant strain ([@B246]). It remains unclear what role these agents will play in the setting the increasing burden of infections with carbapenemase-producing Enterobacteriaceae.

The activity of the siderophore monosulfactam, BAL30072, has been against non-fermenting carbapenemase-producing Gram-negative bacilli ([@B167]). In one study, susceptibility to BAL30072 was noted in 73% of 200 isolates of carbapenemase-producing *A. baumannii*, the majority of which were of the same OXA-23 producing clone ([@B151]). In that same study, smaller percentages of susceptibility were noted in a selection of carbapenem-resistant *Burkholderia cepacia* and *P. aeruginosa* isolates. Recent evaluations of BAL30072 confirm that there may be a role for this agent in the treatment of resistant *A. baumannii* infections ([@B224]; [@B96]). BAL 30376 is a combination of a siderophore monobactam with clavulanic acid. In two studies, this combination demonstrated reasonable *in vitro* activity against CHDL, including OXA-48, and MBLs but not KPCs ([@B129]; [@B168]).

CONCLUDING REMARKS
==================

In the last 5 years, we have witnessed the global spread of carbapenem resistance among Gram-negative organisms. The notion that multidrug resistance among these pathogens is limited to isolated outbreaks among the critically ill has met the ultimate challenge with NDM-1 ([@B114]). The conveniences of travel and medical tourism have introduced resistance mechanisms across states, countries, and even continents at an alarming rate ([@B222]; [@B247]). Rates of resistance in some countries may be underestimated due to the lack of organized reporting structures and limited resources. Long-term healthcare facilities are now recognized reservoirs for the continued propagation of MDR organisms ([@B243]; [@B11]; [@B176]; [@B15]; [@B208]; [@B249]).

Until the introduction of accurate, affordable, and readily accessible diagnostics and reliably effective antimicrobials a major focus remains containment and eradication of these organisms within the healthcare environment. Many cite a "bundle" type approach that includes administrative support, active surveillance, antimicrobial stewardship, and augmented infection control practices ([@B41]; [@B229]; [@B233]). Just as with drug development ([@B239]), the future savings of investing in prevention is not as tangible as the immediate capital investment required to allot appropriate resources including advanced laboratory platforms, experienced laboratory personnel, dedicated nursing staff, and infection control personnel ([@B18]). Expanding these efforts to non-acute healthcare settings is recommended to begin to stem the evolving pandemic of carbapenem resistance ([@B88]).

The prudent use of antibiotics is essential in combating the continuing evolution of resistance ([@B137]). This may be even more crucial in areas where non-prescription antimicrobial use is common and continues to be unregulated. In an age where multidrug resistance is so widespread, even the appropriate use of broad-spectrum antibiotics has contributed to our current state.

Research funding and support for the description of resistance mechanisms, validation of current infection control practices, and antimicrobial development must be prioritized. Institutions supporting infection control, state of the art microbiology laboratories, and antimicrobial stewardship programs should receive recognition and incentives for their foresight. Despite these continuing challenges, considerable progress has been made to identify at-risk populations and to describe resistance determinants. Collaborative efforts ([@B111]; [@B235]; [@B33]) have led to a better understanding and awareness of the epidemiology and the contribution of antimicrobial use and the environment to the propagation of antimicrobial resistance. These joint efforts have proven crucial for the propagation of information about carbapenemases. Continuing to encourage these partnerships is imperative in the ongoing struggle against antimicrobial resistance and to prevent antimicrobials from essentially becoming obsolete.
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